INMED PHARMACEUTICALS INC. Foreign Currency Transaction Gain (Loss), Realized
INMED PHARMACEUTICALS INC. (INM) reported Foreign Currency Transaction Gain (Loss), Realized of $107.43 thousand for the 12-month period ending 2022-06-30, per its 10-K filed 2022-09-23.
Discontinued › Cash Flow › Operating Activities
us-gaap:ForeignCurrencyTransactionGainLossRealized · last filed 2022-09-23
- INMED PHARMACEUTICALS INC. foreign currency transaction gain (loss), realized for fiscal 2021 was 80.71K CAD.
CAD
| Period end | Foreign Currency Transaction Gain (Loss), Realized 12 month |
|---|---|
| 2021-06-30 | 80.71K CAD 10-K · filed 2021-09-24 |
EUR
| Period end | Foreign Currency Transaction Gain (Loss), Realized 12 month |
|---|---|
| 2021-06-30 | 27.43K EUR 10-K · filed 2021-09-24 |
USD
| Period end | Foreign Currency Transaction Gain (Loss), Realized 3 month | Foreign Currency Transaction Gain (Loss), Realized 6 month | Foreign Currency Transaction Gain (Loss), Realized 9 month | Foreign Currency Transaction Gain (Loss), Realized 12 month |
|---|---|---|---|---|
| 2022-06-30 | $72.20K derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-23 | $34.81K derived: sum of 2 quarters · filed 2022-09-23 | $23.63K derived: sum of 3 quarters · filed 2022-09-23 | $107.43K 10-K · filed 2022-09-23 |
| 2022-03-31 | -$37.39K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-05-13 | -$48.57K derived: sum of 2 quarters · filed 2022-05-13 | $35.23K 10-Q · filed 2022-05-13 | $85.56K derived: sum of 4 quarters · filed 2022-09-23 |
| 2021-12-31 | -$11.18K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-02-14 | $72.62K 10-Q · filed 2022-02-14 | $122.95K derived: sum of 3 quarters · filed 2022-09-23 | -$117.91K derived: sum of 4 quarters · filed 2022-09-23 |
| 2021-09-30 | $83.80K 10-Q · filed 2021-11-10 | $134.13K derived: sum of 2 quarters · filed 2022-09-23 | -$106.73K derived: sum of 3 quarters · filed 2022-09-23 | $86.52K derived: sum of 4 quarters · filed 2022-09-23 |
| 2021-06-30 | $50.33K derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-23 | -$190.53K derived: sum of 2 quarters · filed 2022-09-23 | $2.72K derived: sum of 3 quarters · filed 2022-09-23 | $80.71K 10-K · filed 2022-09-23 |
| 2021-03-31 | -$240.86K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-05-13 | -$47.61K derived: sum of 2 quarters · filed 2022-05-13 | $30.39K 10-Q · filed 2022-05-13 | |
| 2020-12-31 | $193.25K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-02-11 | $271.24K 10-Q · filed 2021-02-11 | ||
| 2020-09-30 | $77.99K 10-Q · filed 2020-12-17 | |||
| 2019-12-31 | -$4.68K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-02-11 | $11.25K 10-Q · filed 2021-02-11 | ||
| 2019-09-30 | $15.93K 10-Q · filed 2020-12-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |